VTE Risk in Pregnancy (RCOG)
RCOG Green-top assessment for VTE risk in pregnancy/puerperium to guide LMWH thromboprophylaxis.
Score interpretation
Low VTE risk in pregnancy.
→ No pharmacological prophylaxis required antenatally. Encourage mobilisation. Reassess if hospitalised.
Score 2–3: Intermediate risk.
→ Consider LMWH from 28 weeks. Postnatal LMWH for 10 days. If hospitalised: start LMWH immediately.
Score ≥4: High risk.
→ Antenatal LMWH throughout pregnancy. Postnatal LMWH for at least 6 weeks. Haematology review. Consider compression stockings.
Interpretation bands for the VTE Pregnancy. Apply clinical judgement and local guidance.
References
- RCOG Green-top Guideline No. 37a. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. 2015.
Related
Curated clinical cross-links plus same-class fallbacks.
- Enoxaparin (VTE in Pregnancy) · Low Molecular Weight Heparin (LMWH) — VTE Prophylaxis/Treatment
- Folic Acid (Pre-conception and Pregnancy) · Vitamin / Neural Tube Defect Prevention
- Enoxaparin (LMWH) · Anticoagulant
- Thiamine (IV/IM — Pabrinex) · Vitamin B1 (Thiamine) — deficiency treatment / Wernicke's encephalopathy prevention
- Anthrax Vaccine · Vaccine (Bacterial — Anthrax Prevention)
- Edoxaban (AF Stroke Prevention / VTE) · Direct Factor Xa Inhibitor (DOAC)
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS
- Pre-eclampsia Management · NICE NG133 2019
- Ectopic Pregnancy · NICE CG154 / RCOG GTG 21
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.